Abstract： Conventional imaging techniques and gastrointestinal endoscopy cannot accurately predict the early clinical efficacy of chemoradiotherapy in the treatment of esophageal cancer, whereas the functional imaging of PET-CT,MRI-DWI and radiomics can reflect the functional metabolism of the tumors prior to the morphological changes, which can compensate for the limitations of conventional diagnostic methods. In this article, the current application of imaging techniques in predicting the early response of chemoradiotherapy for esophageal cancer was reviewed.
Liao Ye,Zhao Lina,Shi Mei. Research progress on prediction of early response to chemoradiotherapy of esophageal cancer by multimodal imaging and radiomics[J]. Chinese Journal of Radiation Oncology, 2019, 28(4): 314-316.
[1] van Hagen P,Hulshof MCCM,van Lanschot JJB,et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J].N Engl J Med,2012,366(22):2074-2084.DOI:10.1056/NEJMoa1112088. [2] Heethuis SE,van Rossum PSN,Lips IM,et al. Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy[J].Radiother Oncol,2016,120(1):128-135.DOI:10.1016/j.radonc.2016.05.009. [3] Wang L,Liu L,Han C,et al. The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy[J].Radiother Oncol,2016,121(2):246-251.DOI:10.1016/j.radonc.2016.10.021. [4] Hou Z,Ren W,Li S,et al. Radiomic analysis in contrast-enhanced CT:predict treatment response to chemoradiotherapy in esophageal carcinoma[J].Oncotarget,2017,8(61):104444-104454.DOI:10.18632/oncotarget.22304. [5] van Rossum PSN,van Lier ALHMW,van Vulpen M,et al. Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer[J].Radiother Oncol,2015,115(2):163-170.DOI:10.1016/j.radonc.2015.04.027. [6] Fang P,Musall BC,Son JB,et al. Multimodal imaging of pathologic response to chemoradiation in esophageal cancer[J].Int J Radiat Oncol Biol Phys,2018, 102(4):996-1001.DOI:10.1016/j.ijrobp.2018.02.029. [7] Liu G,Yang Z,Li T,et al. Optimization of b-values in diffusion-weighted imaging for esophageal cancer:measuring the longitudinal length of gross tumor volume and evaluating chemoradiotherapeutic efficacy[J].J Cancer Res Ther,2017,13(5):748-755.DOI:10.4103/jcrt. JCRT_630_17. [8] 杨正汉,冯逢,王霄英.磁共振成像技术指南——检查规范、临床策略及新技术(修订版)[J].中国医学影像学杂志, 2010,18(4):312. Yang ZH,Feng F,Wang XY.Technical guidelines for magnetic resonance imaging:examination specifications,clinical strategies and new technologies (Revised Edition)[J].Chin J Med Imag,2010, 18(4):312. [9] Zhu S,Wei Y,Gao F,et al. Esophageal carcinoma:intravoxel incoherent motion diffusion-weighted MRI parameters and histopathological correlations[J].JMRI,2019, 49(1):253-261.DOI:10.1002/jmri.26172. [10] Tandberg DJ,Cui Y,Rushing CN,et al. Intra-treatment response assessment with 18F-FDG PET:Correlation of semi-quantitative PET features with pathologic response of esophageal cancer to neoadjuvant chemoradiotherapy[J].Int J Radiat Oncol Biol Phys,2018, 102(4):1002-1007.DOI:10.1016/j.ijrobp.2018.07.187. [11] Hou Z,Li S,Ren W,et al. Radiomic analysis in T2W and SPAIR T2W MRI:predict treatment response to chemoradiotherapy in esophageal squamous cell carcinoma[J].J Thorac Dis,2018,10(4):2256-2267.DOI:10.21037/jtd.2018.03.123. [12] Tixier F,Le Rest CC,Hatt M,et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer[J].J Nucl Med,2011,52(3):369-378.DOI:10.2967/jnumed.110.082404. [13] Zhang H,Tan S,Chen W,et al. Modeling pathologic response of esophageal cancer to chemoradiotherapy using spatial-temporal 18F-FDG PET features,clinical parameters,and demographics[J].Int J Radiat Oncol Biol Phys,2014,88(1):195-203.DOI:10.1016/j.ijrobp.2013.09.037. [14] Lynam-Lennon N,Bibby BA,Mongan AM,et al. Low miR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma[J].Mol Med Camb Mass,2016,22.DOI:10.2119/molmed.2016.00020. [15] Otsuka R,Akutsu Y,Sakata H,et al. ZNF750 expression as a novel candidate biomarker of chemoradiosensitivity in esophageal squamous cell carcinoma[J].Oncology,2017,93(1):197-203.DOI:10.1159/000476068. [16] Honing J,Pavlov KV,Mul VEM,et al. CD44,SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy[J].Radiother Oncol,2015,117(1):152-158.DOI:10.1016/j.radonc.2015.08.031. [17] Creemers A,Krausz S,Strijker M,et al. Clinical value of ctDNA in upper-GI cancers:a systematic review and meta-analysis[J].Biochim Biophys Acta BBA-Rev Cancer,2017,1868(2):394-403.DOI:10.1016/j.bbcan.2017.08.002.
2019, Vol. 28 
